Показано 0 из 0
Дата |
---|
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.32
|
1.70
|
1.70
|
1.69
|
1.74
|
1.705
|
|
|
35 091.96
|
166.00
|
1.32
|
1.85
|
1.74
|
1.68
|
1.79
|
1.72
|
|
|
176 940.63
|
371.00
|
1.36
|
1.78
|
1.68
|
1.62
|
1.69
|
1.66
|
|
|
216 650.08
|
429.00
|
1.46
|
1.73
|
1.45
|
1.45
|
1.60
|
1.57
|
|
|
124 802.70
|
536.00
|
1.35
|
1.56
|
1.42
|
1.42
|
1.46
|
1.445
|
|
|
4 867.17
|
55.00
|
1.41
|
1.65
|
1.50
|
1.41
|
1.50
|
1.47
|
|
|
6 360.32
|
58.00
|
1.36
|
1.59
|
1.48
|
1.42
|
1.49
|
1.45
|
|
|
4 766.35
|
48.00
|
1.37
|
1.49
|
1.42
|
1.35
|
1.48
|
1.48
|
|
|
129 939.65
|
559.00
|
1.20
|
2.31
|
1.51
|
1.45
|
1.59
|
1.49
|
|
|
14 244.34
|
97.00
|
|
2.31
|
1.52
|
1.49
|
1.53
|
1.52
|
|
|
3 035.93
|
47.00
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development.